PO-412 Effectiveness and safety of anti-PD1 (Nivolumab) as second line treatment of advanced non-small cell lung cancer (NSCLC) elderly and heavy smokers patients (PTS) with unknown PD-1 status
| Autor: | Fusco, J.P., Acosta, D., Pérez-Carrión, R., Castillo, M. Del, Caviedes, E., Garzón, C., Ramirez, N., Fiorini, A., González-Larriba, J.L. |
|---|---|
| Zdroj: | In ESMO Open 30 June-3 July 2018 3 Supplement 2:A391-A391 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|